Changed expression of E-cadherin and galectin-9 in oral squamous cell carcinomas but lack of potential as prognostic markers

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 5, 2014, Pages 2145-2152

  Chan, Siew Wui ^a   Kallarakkal, Thomas George ^a   Abraham, Mannil Thomas ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b Hospital Tengku Ampuan Rahimah   (Malaysia)

Author keywords

E cadherin; Galectin 9; Oral squamous cell carcinoma; Prognostic markers

Indexed keywords

CADHERIN; GALECTIN; LGALS9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; CROSS-SECTIONAL STUDY; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; MOUTH MUCOSA; MOUTH TUMOR; PATHOLOGY; PROCEDURES; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, SQUAMOUS CELL; CROSS-SECTIONAL STUDIES; FEMALE; GALECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84899064113     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.5.2145     Document Type: Article

References (57)

1. Alberts B, Johnson A, Lewis J, et al (2002). Cell-Cell Adhesion. Molecular Biology of the Cell. 4 ed. New York: Garland Science.
2. Alves PM, Godoy GP, Gomes DQ, et al (2011). Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue. Pathol Res Pract, 207, 236-40.
3. Balan V, Nangia-Makker P, Raz A (2010). Galectins as cancer biomarkers. Cancers, 2, 592-610.
4. Berchuck A, Soisson AP, Clarke-Pearson DL, et al (1989). Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. Cancer Res, 49, 2091-5.
5. Bosch FX, Abel U, Kartenbeck J (2005). E-cadherin is a selective and strongly dominant prognostic factor in squamous cell carcinoma: a comparison of E-cadherin with desmosomal components. Int J Cancer, 114, 779-90.
6. Cada Z, Smetana K Jr, Lacina L, et al (2009). Immunohistochemical fingerprinting of the network of seven adhesion/growthregulatory lectins in human skin and detection of distinct tumour-associated alterations. Folia Biologica, 55, 145-52.
7. Cerezo L (2011). Is loss of cadherin expression predictive of high aggressiveness in oropharyngeal squamous cell carcinoma?. Oral Oncology, 47, 685.
8. Chen HY, Lo CH, Li CS, Hsu DK, Liu FT (2012). Galectins and cutaneous immunity. Dermatologica Sinica, 30, 121-7.
9. Christofori G & Semb H (1999). The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci, 24, 73-6.
10. Cooper DN, Barondes SH (1999). God must love galectins; he made so many of them. Glycobiology, 9, 979-84.
11. Diniz-Freitas M, Garcia-Caballero T, Antunez-Lopez J, Gandara-Rey JM, Garcia-Garcia A (2006). Reduced E-cadherin expression is an indicator of unfavourable prognosis in oral squamous cell carcinoma. Oral Oncol, 42, 190-200.
12. Dorta RG, Landman G, Kowalski LP, et al (2002). Tumourassociated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology, 41, 152-7.
13. Edge SE, Byrd DR, Compton CC, et al (2010). AJCC Cancer Staging Manual New York, USA, Springer.
14. Fik Z, Valach J, Chovanec M, et al (2013). Loss of adhesion/ growth-regulatory galectin-9 from squamous cell epithelium in head and neck carcinomas. J Oral Pathol Med, 42, 166-73.
15. Foschini MP, Cocchi R, Morandi L, et al (2008). E-cadherin loss and Delta Np73L expression in oral squamous cell carcinomas showing aggressive behavior. Head & Neck, 30, 1475-82.
16. Foschini MP, Leonardi E, Eusebi LH, et al (2013). Podoplanin and E-cadherin expression in preoperative incisional biopsies of oral squamous cell carcinoma is related to lymph node metastases. Int J Surg Pathol, 21, 133-41.
17. Friedrichs J, Torkko JM, Helenius J, et al (2007). Contributions of galectin-3 and -9 to epithelial cell adhesion analyzed by single cell force spectroscopy. J Biol Chem, 282, 29375-83.
18. Hirashima M (2003). Multi-functions of Galectin-9. Mod Asp Immunobiol, 3, 6.
19. Honjo Y, Inohara H, Akahani S, et al (2000). Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res, 6, 4635-40.
20. Hung KF, Chang CS, Liu CJ, et al (2006). Differential expression of E-cadherin in metastatic lesions comparing to primary oral squamous cell carcinoma. J Oral Pathol Med, 35, 589-94.
21. Irie A, Yamauchi A, Kontani K,et al (2005). Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res, 11, 2962-8.
22. Kageshita T, Kashio Y, Yamauchi A, et al (2002). Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer, 99, 809-16.
23. Kasamatsu A, Uzawa K, Nakashima D, et al (2005). Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int J Mol Med, 16, 269-73.
24. Kitawaki J, Kusuki I, Koshiba H, et al (1999). Detection of aromatase cytochrome P-450 in endometrial biopsy specimens as a diagnostic test for endometriosis. Fertil Steril, 72, 1100-6.
25. Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F (2004). Introduction to galectins. Glycoconj J, 19, 433-40.
26. Li JJ, Zhang GH, Yang XM, et al (2012). Reduced E-cadherin expression is associated with lymph node metastases in laryngeal squamous cell carcinoma.
27. Liang M, Ueno M, Oomizu S, et al (2008). Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J Cancer Res Clin Oncol, 134, 899-907.
28. Liu LK, Jiang XY, Zhou XX, et al (2010). Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol, 23, 213-24.
29. Lopes FF, Da Costa Miguel MC, Pereira ALA, et al (2009). Changes in immunoexpression of E-cadherin and betacatenin in oral squamous cell carcinoma with and without nodal metastasis. Ann Diagn Pathol, 13, 22-9.
30. Mahomed F, Altini M, Meer S (2007). Altered E-cadherin/ beta-catenin expression in oral squamous carcinoma with and without nodal metastasis. Oral Diseases, 13, 386-92.
31. Marsh R, Brackenbury R (1996). Molecules of cell adhesion and recognition: An overview. In: LEE, A. G. (ed.) Biomembranes: Receptors of cell adhesion and cellular recognition. JAI Press Inc.
32. Matsumoto R, Matsumoto H, Seki M, et al (1998). Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem, 273, 16976-84.
33. Menezes MB, Lehn CN, Gon Alves AJ (2007). Epidemiological and histopathological data and E-cadherin-like prognostic factors in early carcinomas of the tongue and floor of mouth. Oral Oncology, 43, 656-61.
34. Mostaan LV, Khorsandi MT, Sharifian SMR, et al (2011). Correlation between E-cadherin and CD44 adhesion molecules expression and cervical lymph node metastasis in oral tongue SCC: Predictive significance or not. Pathol Res Pract, 207, 448-51.
35. Murase N, Hosaka M, Takai Y, Tanimura T, Mori M (1985). Histochemical demonstration of lectinbinding sites and keratin in inflamed human gingiva. J Periodontal Res, 20, 625-36.
36. Nakahara S, Raz A (2008). Biological modulation by lectins and their ligands in tumor progression and metastasis. Anticancer Agents Med Chem, 8, 22-36.
37. Neville BW, Day TA (2002). Oral cancer and precancerous lesions. CA Cancer J Clin, 52, 195-215
38. Nijkamp MM, Span PN, Hoogsteen IJ, et al (2011). Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol, 99, 344-8.
39. Pioche-Durieu C, Keryer C, Souqu Re S, et al (2005). In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. J Virol, 79, 13326-37.
40. Rabinovich GA, Rubinstein N, Toscano MA (2002). Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta, 1572, 274-84.
41. Rao SVK, Mejia G, Roberts-Thomson K, Logan R (2013). Epidemiology of oral cancer in Asia in the past decade-an update (2000-2012). Asian Pac J Cancer Prev, 14, 5567-77.
42. Rosado P, Lequerica-Fernandez P, Fernandez S, et al (2013). E-cadherin and β-catenin expression in well-differentiated and moderately-differentiated oral squamous cell carcinoma: relations with clinical variables. Br J Oral Maxillofac Surg, 51, 149-56.
43. Sahu N, Grandis JR (2011). New advances in molecular approaches to head and neck squamous cell carcinoma. Anti-Cancer Drugs, 22, 656-64.
44. Saussez S, Camby I, Toubeau G and Kiss R (2007). Galectins as modulators of tumor progression in head and neck squamous cell carcinomas. Head & Neck, 29, 874-84.
45. Schipper JH, Frixen UH, Behrens J, et al (1991). E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Research, 51, 6328-37.
46. Schneider PM, Baldus SE, Metzger R, et al (2005). Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg, 242, 684-92.
47. Scully C, Bagan J (2009). Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Diseases, 15, 388-99.
48. Smetana K Jr, Dvor Nkov B, Chovanec M, et al (2006). Nuclear presence of adhesion-/growth-regulatory galectins in normal/ malignant cells of squamous epithelial origin. Histochem Cell Biol, 125, 171-82.
49. Stewart BWW, Kleihues PI (2008). World cancer report, IARC Press.
50. Suzuki T, Sadahiro S, Fukasawa M, et al (2004). Predictive factors of tumor shrinkage and histological regression in patients who received preoperative radiotherapy for rectal cancer. Jpn J Clin Oncol, 34, 740-6.
51. Tanaka N, Odajima T, Ogi K, Ikeda T, Satoh M (2003). Expression of E-cadherin, alpha-catenin, and beta-catenin in the process of lymph node metastasis in oral squamous cell carcinoma. Br J Cancer, 89, 557-63.
52. Ukpo OC, Thorstad WL, Zhang Q, Lewis JS Jr (2012). Lack of association of cadherin expression and histopathologic type, metastasis, or patient outcome in oropharyngeal squamous cell carcinoma: a tissue microarray study. Head Neck Pathol, 6, 38-47.
53. Wang X, Zhang J, Fan M, et al (2009). The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: immunohistochemical and RT-PCR analysis with clinicopathological correlation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 107, 547-54.
54. Woolgar JA (2006). Histopathological prognosticators in oral and oropharyngeal squamous cell carcinoma. Oral Oncol, 42, 229-39.
55. Yamada K, Jordan R, Mori M, Speight PM (1997). The relationship between E-cadherin expression, clinical stage and tumour differentiation in oral squamous cell carcinoma. Oral Diseases, 3, 82-5.
56. Zhao Z, Ge J, Sun Y, et al (2012). Is E-cadherin immunoexpression a prognostic factor for head and neck squamous cell carcinoma (HNSCC)? A systematic review and metaanalysis. Oral Oncol, 48, 761-7.
57. Zhong LP, Li J, Zhang CP, et al (2007). Expression of E-cadherin in cervical lymph nodes from primary oral squamous cell carcinoma patients. Arch Oral Biol, 52, 740-7.